EA201890769A1 - Производные 2,3,4,5-тетрагидропиридин-6-амина - Google Patents
Производные 2,3,4,5-тетрагидропиридин-6-аминаInfo
- Publication number
- EA201890769A1 EA201890769A1 EA201890769A EA201890769A EA201890769A1 EA 201890769 A1 EA201890769 A1 EA 201890769A1 EA 201890769 A EA201890769 A EA 201890769A EA 201890769 A EA201890769 A EA 201890769A EA 201890769 A1 EA201890769 A1 EA 201890769A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- dementia
- beta
- tetrahydropyridin
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Настоящее изобретение относится к ингибиторам бета-секретазы, представляющим собой соединения 2,3,4,5-тетрагидропиридин-6-амина, имеющие структуру, представленную в формуле (I)где радикалы определены в описании изобретения. Настоящее изобретение также направлено на фармацевтические композиции, содержащие такие соединения, на способы получения таких соединений и композиций и на применение таких соединений и композиций для предупреждения и лечения расстройств, в которые вовлечена бета-секретаза, таких как болезнь Альцгеймера (AD), умеренное когнитивное нарушение, угасание, деменция, деменция с тельцами Леви, синдром Дауна, деменция, ассоциированная с инсультом, деменция, ассоциированная с болезнью Паркинсона, или деменция, ассоциированная с бета-амилоидом.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15186394 | 2015-09-23 | ||
EP16172005 | 2016-05-30 | ||
PCT/EP2016/072710 WO2017050978A1 (en) | 2015-09-23 | 2016-09-23 | 2,3,4,5-tetrahydropyridin-6-amine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201890769A1 true EA201890769A1 (ru) | 2018-09-28 |
EA035026B1 EA035026B1 (ru) | 2020-04-20 |
Family
ID=56985626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890769A EA035026B1 (ru) | 2015-09-23 | 2016-09-23 | Производные 2,3,4,5-тетрагидропиридин-6-амина |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180334447A1 (ru) |
EP (1) | EP3353163B1 (ru) |
JP (1) | JP2018527387A (ru) |
KR (1) | KR20180053357A (ru) |
CN (1) | CN108026069A (ru) |
AU (1) | AU2016328589A1 (ru) |
BR (1) | BR112018005591A2 (ru) |
CA (1) | CA2995161A1 (ru) |
EA (1) | EA035026B1 (ru) |
HK (1) | HK1254800A1 (ru) |
IL (1) | IL258217A (ru) |
MX (1) | MX2018003565A (ru) |
TW (1) | TW201726651A (ru) |
WO (1) | WO2017050978A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210261561A1 (en) * | 2018-04-23 | 2021-08-26 | Shionogi & Co., Ltd. | Bicyclic heterocycle derivatives having selective bace1 inhibitory activity |
US11629154B2 (en) | 2018-04-27 | 2023-04-18 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
CN114380736B (zh) * | 2020-10-21 | 2023-10-03 | 复旦大学 | 一种2,3,4,5-四氢吡啶类化合物的合成方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077328A1 (es) * | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
US8815841B2 (en) | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
US9556135B2 (en) * | 2012-10-12 | 2017-01-31 | Amgen, Inc. | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
EP2961749B1 (en) | 2013-03-01 | 2019-10-09 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
AU2015220873A1 (en) * | 2014-02-19 | 2016-08-11 | H. Lundbeck A/S | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease |
-
2016
- 2016-09-21 TW TW105130403A patent/TW201726651A/zh unknown
- 2016-09-23 KR KR1020187010344A patent/KR20180053357A/ko unknown
- 2016-09-23 CN CN201680055231.XA patent/CN108026069A/zh active Pending
- 2016-09-23 US US15/761,304 patent/US20180334447A1/en not_active Abandoned
- 2016-09-23 EP EP16770283.6A patent/EP3353163B1/en active Active
- 2016-09-23 WO PCT/EP2016/072710 patent/WO2017050978A1/en active Application Filing
- 2016-09-23 JP JP2018514794A patent/JP2018527387A/ja active Pending
- 2016-09-23 MX MX2018003565A patent/MX2018003565A/es unknown
- 2016-09-23 BR BR112018005591A patent/BR112018005591A2/pt not_active Application Discontinuation
- 2016-09-23 EA EA201890769A patent/EA035026B1/ru not_active IP Right Cessation
- 2016-09-23 AU AU2016328589A patent/AU2016328589A1/en not_active Abandoned
- 2016-09-23 CA CA2995161A patent/CA2995161A1/en not_active Abandoned
-
2018
- 2018-03-19 IL IL258217A patent/IL258217A/en unknown
- 2018-10-31 HK HK18113885.1A patent/HK1254800A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017050978A1 (en) | 2017-03-30 |
EP3353163A1 (en) | 2018-08-01 |
IL258217A (en) | 2018-05-31 |
JP2018527387A (ja) | 2018-09-20 |
BR112018005591A2 (pt) | 2018-10-09 |
HK1254800A1 (zh) | 2019-07-26 |
TW201726651A (zh) | 2017-08-01 |
EA035026B1 (ru) | 2020-04-20 |
AU2016328589A1 (en) | 2018-03-01 |
KR20180053357A (ko) | 2018-05-21 |
CN108026069A (zh) | 2018-05-11 |
EP3353163B1 (en) | 2020-02-05 |
MX2018003565A (es) | 2018-06-18 |
US20180334447A1 (en) | 2018-11-22 |
CA2995161A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
CY1120846T1 (el) | 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1 | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA202091709A1 (ru) | Ингибиторы днк-пк | |
EA201791367A1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
EA201691447A1 (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
EA201291435A1 (ru) | Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace) | |
EA201791030A1 (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
EA201391296A1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
EA201391251A1 (ru) | ПРОИЗВОДНЫЕ 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
EA201491116A1 (ru) | Производные 6-дифторметил-5,6-дигидро-2h-[1,4]оксазин-3-амина | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
EA202090414A1 (ru) | Соединения и их применение | |
EA201791804A1 (ru) | Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
EA201890769A1 (ru) | Производные 2,3,4,5-тетрагидропиридин-6-амина | |
EA201991898A1 (ru) | Двойные ингибиторы magl и faah | |
EA201992055A1 (ru) | Ингибиторы бета-секретазы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |